Evidence map›Paper›PMID 28840414›Full record

ArticleMolecular diversity2017

Bis-spirochromanones as potent inhibitors of Mycobacterium tuberculosis: synthesis and biological evaluation.

Ashok Dongamanti, Vikas Kumar Aamate, Mohan Gandhi Devulapally, Srinivas Gundu, Saikrishna Balabadra, Vijjulatha Manga, Perumal Yogeeswari, Dharmarajan Sriram, Sridhar Balasubramanian

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Chromanone-A Prerogative Therapeutic Scaffold: An Overview.Arabian journal for science and engineering · 2022
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ashok DongamantiGreen and Medicinal Chemistry Lab, Department of Chemistry, Osmania University, Hyderabad, Telangana State, 500 007, India. ashokdou@gmail.com.
Vikas Kumar AamateGreen and Medicinal Chemistry Lab, Department of Chemistry, Osmania University, Hyderabad, Telangana State, 500 007, India.
Mohan Gandhi DevulapallyGreen and Medicinal Chemistry Lab, Department of Chemistry, Osmania University, Hyderabad, Telangana State, 500 007, India.
Srinivas GunduGreen and Medicinal Chemistry Lab, Department of Chemistry, Osmania University, Hyderabad, Telangana State, 500 007, India.
Saikrishna BalabadraMolecular Modeling and Medicinal Chemistry group, Department of Chemistry, Osmania University, Hyderabad, Telangana State, 500 007, India.
Vijjulatha MangaMolecular Modeling and Medicinal Chemistry group, Department of Chemistry, Osmania University, Hyderabad, Telangana State, 500 007, India.
Perumal YogeeswariDepartment of Pharmacy, Birla Institute of Technology and Science - Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad, Telangana State, 500 078, India.
Dharmarajan SriramDepartment of Pharmacy, Birla Institute of Technology and Science - Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad, Telangana State, 500 078, India.
Sridhar BalasubramanianX-ray Crystallography Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, Telangana State, 500 007, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On the basis of reported antimycobacterial property of chroman-4-one pharmacophore, a series of chemically modified bis-spirochromanones were synthesized starting from 2-hydroxyacetophenone and 1,4-dioxaspiro[4.5] decan-8-one using a Kabbe condensation approach. The synthesized bis-spirochromanones were established based on their spectral data and X-ray crystal structure of 6e. All synthesized compounds were evaluated against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain, finding that some products exhibited good antimycobacterial activity with minimum inhibitory concentration as low as [Formula: see text]. Docking studies were carried out to identify the binding interactions of compounds II, 6a and 6n with FtsZ. Compounds exhibiting good in vitro potency in the MTB MIC assay were further evaluated for toxicity using the HEK cell line.

Indexed as

Antitubercular AgentsBacterial ProteinsChemistry Techniques, SyntheticChromansHEK293 CellsHumansMicrobial Sensitivity TestsMolecular Docking SimulationMycobacterium tuberculosisProtein ConformationSpiro CompoundsStructure-Activity RelationshipAntitubercular AgentsBacterial ProteinsChromansSpiro Compounds4-ChromanoneBis-spirochromanonesDockingMycobacterium tuberculosisSpirochromanone

Identifiers

PMID28840414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.